

Executive Summary of Collaboration Agreement:

Project name: CAR-T Simulation Course

Organisations involved: Gilead Sciences Ltd and St George's University Hospitals NHS Foundation Trust

Project Overview:

The provision of CAR T-cell therapy products is restricted to specialist treatment centres that require commissioning from the NHS. These centres may not have previously used and gained experience in providing CAR-T products unless in limited clinical trial settings. St. Georges Hospital Advanced Patient Simulation and Skills Centre have developed a simulation training program to provide clinicians at St George's Hospital with practical experience in developing their skills and familiarising themselves with CAR-T patient counselling and management in a mock(simulated) scenario. Currently this course is only offered to the clinical team within St Georges Hospital.

This collaborative working project aims to make available a new iteration of this training course to clinicians from other NHS Trusts that would benefit from this education.

Project Objectives:

To provide three 1-day simulation (approximately 7 hours) training courses to healthcare professionals with the aim to:

- improve the confidence and knowledge of medical and nursing personnel on the CAR-T patient pathway.
- improve communication competencies with patients relating to CAR-T therapy.
- improve the knowledge of the management CAR-T related toxicities.

Each 1-day training course will consist of approximately 15-20 active participants. Healthcare professionals that are involved within the CAR-T treatment pathway and/or may be involved in managing CAR-T patients will be invited; these may consist of but not exclusively: senior and junior hospital physicians, nurses, pharmacists, allied healthcare professionals and GPs.

These clinicians will be invited from centres that have either recently been qualified to deliver CAR-T but have limited experience, centres that are due to be qualified but have not yet delivered CAR-T and for centres that refer and/or receive patients that have been treated with CAR-T at other centres.

The following **patient benefits** are anticipated:

- Patients counselled on the CAR-T pathway will feel more confident and empowered to participate in shared-care decision making.
- Patient care will be improved through the knowledge and skills gained on this course by healthcare professionals.

The following **benefits to the NHS** are anticipated

- Training for healthcare professionals that would not normally receive simulation based training
- Increased confidence of the healthcare team in managing patients with CAR-T related toxicities.
- Increased confidence of the healthcare team in communicating with patients relating to the CAR-T pathway.
- Closer collaboration within the multi-disciplinary team in managing CAR-T patients.
- Education to healthcare professionals on the CAR-T treatment pathway.
- Showcasing best practice on training of specialist services.

The following **benefits to Gilead** are anticipated:

- Gilead will receive a better understanding of the management of CAR-T patient toxicities in a clinical setting.

UK-UNB-4704 10/2023

- Identification of training and education that would improve the Gilead onboarding process for soon to be qualified CAR-T centres.
- Better understanding of the challenges faced by the NHS in delivering specialist patient services and care.

Contact:

For more information, please contact Lohit Pindoria (Associate Director, Medical Affairs)

lohit.pindoria@gilead.com